Pfizer PFE0.69%increase; green up pointing triangle said it is voluntarily withdrawing all lots of its sickle-cell drug Oxbryta in all markets where it is approved, two years after acquiring its ...

Pfizer has withdrawn Oxbryta and discontinued clinical trials due to safety concerns and an imbalance in fatal events. Oxbryta contributed $92 million in sales during Q2 2024 but is now under ...

Pfizer has announced the voluntary withdrawal of all lots of OXBRYTA (voxelotor) approved for treating sickle cell disease (SCD) from worldwide markets. The company is also discontinuing all ...

Oxbryta (volexator) is a brand-name drug prescribed to treat sickle cell disease (SCD) in adults and some children. Oxbryta comes in two different oral forms and is taken once per day. Oxbryta is ...

The pharmaceutical giant last week announced it would voluntarily withdraw its sickle cell disease therapy, Oxbryta, from worldwide markets — to the surprise of doctors, patients and investors.

It had started last January, just shy of her 27th birthday, when she’d called to get a refill of a sickle cell drug called Oxbryta. There was some mix-up with her insurers; they wouldn’t pay ...

You can reach Jason on Signal at JasonMast.05. Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of ...

Takeaway: The suit is the latest in a string of suits filed following the recall of Oxbryta, a drug used to treat sickle-cell disease. Lawyers: Marcus J. Bradley and Kiley Lynn Grombacher of ...

Oxbryta, one of at least six treatments for the disease, is mostly used in patients with mild-to-moderate symptoms. The drug received accelerated approved in the U.S. in 2019, requiring further ...

“Pfizer’s decision is based on the totality of clinical data that now indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle-cell patient population ...

The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of Pfizer's (PFE.N), opens new tab sickle cell disease treatment Oxbryta.